DiagnosTear is a leading ophthalmic company developing and commercializing disruptive diagnostic solutions for better management of eye diseases. DiagnosTear’s TeaRx™ technology is a diagnostic platform intended for Point-of-Care Testing (POCT) of ophthalmic pathologies through multi-parameter composition analysis of the tear fluid. TeaRx™ technology is based on a minute sample of tear fluid taken with a unique, single-use, microfluidic tear collection device, followed by a semi-quantitative multi-parameter immunoassay, visual or digital readout and cloud-based analysis providing intuitive interpretation of the results. The whole procedure takes less than 10 minutes, is easy to perform and apart from the hand-held test reader (supplied by DiagnosTear), does not require sophisticated, expensive, or space-consuming instrumentation. The first CE-IVD approved test based on the TeaRx™ platform is intended for the identification and monitoring of Dry Eye Syndrome (DES), a common disorder in which there is a decline in tear production or tear quality is impaired. Moderate and severe DES may cause pain and discomfort, and impair vision quality. Some 340 million people worldwide have DES, including some 40 million in the United States. Beyond DES, DiagnosTear is developing innovative tests based on the TeaRx™ platform for additional ophthalmic indications. Among others, DiagnosTear’s pipeline tests include TeaRx™ Red Eye; The first test of its kind for differential assessment of adenoviral conjunctivitis, Herpetic Keratitis and Allergic conjunctivitis. This test is intended to be used by primary care physicians (GPs, family practitioners and pediatricians) as well as by ophthalmologists and is envisioned to allow on-site diagnosis of viral vs. allergic Red Eye and aid the physician in prescribing the optimal treatment and/or refer the patient for further examinations.
